药品信息:
--------------------------------------------------------------- 详细处方信息以本药内容附件PDF文件(201882923330625.pdf)的“原文Priscribing Information”为准 --------------------------------------------------------------- 部分中文替TASMAR处方资料(仅供参考)
药物名称:托卡朋
英文名称:Tolcapone
中文别名:答是美
英文别名:Tasmar
药理作用:
托卡朋为选择性儿茶酚胺氧位甲基转移酶(C0MT)抑制剂,在脑内、脑外均起作用,可阻止多巴转变成3-O-甲基多巴,3-O-甲基多巴能与左旋多巴竞争入脑,其含量降低可促进左旋多巴进入脑内而加强左旋多巴疗效。
适应症:
本品适用于帕金森病及其综合征,为左旋多巴的辅助用药。对左旋多巴治疗帕金森病时出现的“剂末药效减退”和“开-关现象”有效。
用法用量:
口服:成人每次100~200mg,每日3次。必须与多巴胺同时服用。
不良反应:
常见的不良反应有运动障碍、失眠、恶心、呕吐及肝损害。偶见直立性低血压。
注意事项:
肝功能不良者慎用。
疗效评价:
有报道称托卡朋可导致致命性肝坏死,故仅推荐在无严重的运动障碍且其他药物无效时使用,且在用药过程中应注意监测肝功能。
Drug Name: Tokapeng
English name: Tolcapone
Chinese alias: A is beautiful
English alias: Tasmar
Pharmacological action:
Tokapeng is a selective catecholamine O-methyltransferase (C0MT) inhibitor that acts both in the brain and outside the brain to prevent the conversion of dopa to 3-O-methyldopa, 3-O-methyl Dopa competes with levodopa for brain, and its reduced content can promote levodopa into the brain and enhance the efficacy of levodopa.
Indications:
This product is suitable for Parkinson's disease and its syndrome, and is an adjuvant medication for levodopa. It is effective for the treatment of Parkinson's disease when levodopa is used, and the "drug-effect reduction" and "on-off phenomenon" appear.
Usage and usage:
Oral: 100 to 200 mg per adult, 3 times a day. Must be taken at the same time as dopamine.
Adverse reactions:
Common adverse reactions are dyskinesia, insomnia, nausea, vomiting, and liver damage. Occasionally, erect hypotension.
Note:
Patients with liver dysfunction should be used with caution.
Efficacy evaluation:
It has been reported that tokapone can cause fatal liver necrosis, so it is only recommended to use without serious dyskinesia and other drugs are ineffective, and should pay attention to monitoring liver function during the medication.
--------------------------------------------------------------- 详细处方信息以本药内容附件PDF文件(201882923330625.pdf)的“原文Priscribing Information”为准 ---------------------------------------------------------------
2011-4-7更新 |